To further assess the potential relevance of the combinatorial therapy, we performed in vivo experiments, by treating RAS/BRAF wt CRC patient-derived-xenograft (PDX) models sensitive to anti-EGFR antibodies. Here, BRAF is linked to colorectal carcinoma.